SL1703 / Beijing GoBroad Hospital, SenlangBio - LARVOL DELTA

Tandem CD19/BCMA CAR T-Cell Therapy in Refractory/Progressive Systemic Sclerosis: Early Immune Remodeling and Skin Response (ACR Convergence 2026) - No abstract available

CAR T-Cell Therapy • Immunology • Scleroderma • Systemic Sclerosis

Tandem CD19/BCMA CAR T-Cell Therapy in Refractory or Progressive Systemic Sclerosis: Early Multidomain Clinical and Immune Remodeling (ACR Convergence 2026) - No abstract available

CAR T-Cell Therapy • Clinical • Immunology • Scleroderma • Systemic Sclerosis

Dual-Axis CD19/BCMA CAR T-Cell Therapy in Refractory Systemic Sclerosis-Overlap Connective Tissue Disease: Target Engagement, Skin Improvement, and Humoral Immune Reset (ACR Convergence 2026) - No abstract available

CAR T-Cell Therapy • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

Clinical Activity and Day-15 Immune Reconfiguration After Tandem CD19/BCMA CAR T-Cell Therapy in Refractory Systemic Lupus Erythematosus (ACR Convergence 2026) - No abstract available

CAR T-Cell Therapy • Clinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Clinical Efficacy Angle – Sustained Remission in Refractory Systemic Sclerosis with Dual-Target CAR-T Therapy (EULAR 2026) - "Methods Eleven adult SSc patients (10 female, median age 35 years; 9 diffuse cutaneous SSc) with refractory disease (median duration 4 years; prior immunosuppressants including cyclophosphamide and rituximab) received autologous CD19/BCMA CAR-T cells (dose 1.0-2.2×10^6/kg) after lymphodepletion. Conclusions Dual-target CD19/BCMA CAR-T induces profound, sustained clinical remission in refractory SSc, targeting skin fibrosis and lung progression without relapse. This "reset" strategy offers a curative potential, warranting phase II trials to redefine SSc management."

CAR T-Cell Therapy • Clinical • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis

An Immunological Reset is Not Enough: A Prospective Study of Dual CD19/BCMA CAR-T in SLE Defines a Histological "Point of No Return" for Organ Recovery (EULAR 2026) - "Patients were pre- conditioned with Fludarabine (25mg/m2) / Cyclophosphamide (250 mg/m2). However, renal recovery was heterogeneous and appeared constrained by pre-existing chronic structural damage. This supports a time- sensitive window for organ salvage before advanced chronicity is established, providing a compelling rationale for a paradigm shift: deploying dual-target CAR-T as an early intervention to prevent, rather than salvage, irreversible organ damage."

CAR T-Cell Therapy • Clinical • IO biomarker • Infectious Disease • Inflammatory Arthritis • Lupus • Nephrology • Renal Disease • Systemic Lupus Erythematosus • CD27

Comprehensive Immunological Reset in Systemic Sclerosis: Dual Depletion of B Cells and Plasma Cells via CD19/BCMA CAR-T Therapy Eradicates Pathogenic Autoimmunity (EULAR 2026) - "Significant reductions in ANA and specific antibody titers were observed, surpassing effects typically seen with Rituximab. Conclusions Targeting BCMA in addition to CD19 effectively eliminates the niche of autoreactive plasma cells resistant to conventional B-cell depletion. This study provides the mechanistic proof-of-concept that CD19/BCMA CAR-T therapy induces a true immunological reset, validating its rationale as a potentially curative strategy for autoantibody-driven SSc."

CAR T-Cell Therapy • Immunology • Infectious Disease • Scleroderma • Systemic Sclerosis • CD27 • SDC1

Bridging with Calcium Disodium Edetate (CaNa₂EDTA) to Potentiate Autologous Tandem CD19-BCMA CAR-T Therapy in Refractory Diffuse Systemic Sclerosis: A Pilot "Microenvironment-Remodeling" Study (EULAR 2026) - "All patients underwent a lymphodepletion regimen consisting of fludarabine (25 mg/m²) and cyclophosphamide (250 mg/m²). Concomitant immunosuppressants were discontinued before lymphodepletion; physiologic-dose glucocorticoids ( ≤ 20 mg/day prednisone equivalent) were allowed...No anti-IL-6 therapy (tocilizumab) was required for bridged patients...No anti-IL-6 therapy (tocilizumab) was required for bridged patients...HAQ-DI scores decreased by 83% (vs. 61%). All patients had ILD on baseline HRCT; pulmonary function remained stable or improved longitudinally in the Bridging Cohort."

CAR T-Cell Therapy • IO biomarker • Fibrosis • Immunology • Infectious Disease • Scleroderma • Systemic Sclerosis

Deep Immunological Reset and Reversal of Fibrosis in Refractory Systemic Sclerosis: A Pilot Study of Tandem CD19-BCMA CAR-T Therapy (ARA 2026) - "Following lymphode - pletion (cyclophosphamide/fludarabine), patients received a single infusion of autologous tandem 19- BCMA CAR- T cells...Grade 1 cytokine re - lease syndrome (CRS), manifesting as fever, occurred in 6/8 pa - tients; all resolved with supportive care without tocilizumab... Autologous tandem CD19- BCMA CAR- T ther - apy demonstrates superior tolerability and potent dual- efficacy. The ability to reverse severe fibrosis and improve lung function without high- grade toxicity suggests this approach successfully induces a deep immunological reset, representing a potential paradigm shift in treating refractory SSc"

CAR T-Cell Therapy • Clinical • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis

THE "WINDOW OF OPPORTUNITY" IN CAR-T FOR LUPUS NEPHRITIS: AUTOLOGOUS BISPECIFIC CD19/BCMA RESCUE IN PATIENTS REFRACTORY TO UNIVERSAL-CD19 CAR-T — A TALE OF TWO BIOPSIES (EBMT 2026) - "While autologous bispecific CD19/BCMA CAR-T offers a definitive immunological salvage by depleting the entire B-cell lineage, the potential for renal recovery in advanced disease remains undefined... Autologous 19-BCMA CAR-T is a highly effective salvage strategy for immunological relapse, reliably inducing deep serological remission where universal CD19 therapy fails. However, our data unmask a critical limitation: Immunological cure does not guarantee organ restitution if the "Window of Opportunity" is missed. A Chronicity Index (CI) ≥ 5 may predict persistent proteinuria despite successful B-cell eradication."

Biopsy • Bispecific • CAR T-Cell Therapy • Clinical • IO biomarker • Fibrosis • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Beijing GoBroad Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2026 ➔ Dec 2027 | Initiation date: Sep 2025 ➔ Mar 2026

Enrollment open • Trial completion date • Trial initiation date • Cardiovascular • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • CD19

A tandem bispecific nanobody CAR (SL1703) T cells targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure (ASH 2025) - P1 | "Two patients relapsed and died at 6 months, while the others remained remission. Conclusion The novel tandem bispecific nanobody-based CD19/BCMA CAR-T cell therapy might rescue the failure ofprevious BCMA CAR-T therapy.The phase 1 clinical trial has been registered and isrecruiting(NCT07003555)."

Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients (ASH 2025) - P1/2 | "Their persistent killing capacity against CD19+ or BCMA+ targets was comparable to that of singleCD19 or BCMA CAR-T cells. Novel Loop dual CD19/BCMA CAR-T demonstrated favorable efficacy and safety inrelapsed/refractory autoimmune diseases and new clinical trial is ongoing (NCT06947460)."

Clinical • IO biomarker • Cardiovascular • Fibrosis • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lupus Nephritis • Nephrology • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis

Big Announcement | Senlang Biotechnology’s 6 Cutting-Edge Achievements to be Showcased at ASH2025 [Google translation] (Senlang Biotech Press Release) - "The company will officially release six of its latest clinical research findings during the conference, including its core products: CD7-targeted SENL101, CD19/BCMA dual-targeted SL1703, CD19/CD20 dual-targeted SL1716, and BCMA/GPRC5D dual-targeted SL0439."

Clinical data • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (clinicaltrials.gov) - P1/2 | N=45 | Not yet recruiting | Sponsor: Beijing GoBroad Hospital | Initiation date: May 2025 ➔ Sep 2025

Trial initiation date • Cardiovascular • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis